Zanubrutinib as Third-Line and Beyond Therapy for FL

Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.

Related Keywords

Laurie Sehn , ,Recent Updates ,Follicular Lymphoma ,Mantle Cell Lymphoma ,Beyond Therapy ,Fl ,Zanubrutinib ,Third Line Therapy ,Third Line And Beyond ,Obinutuzumab ,Durable Response ,Lenalidomide ,Fda Approval ,Augment Trial ,Rosewood Trial ,Btk Inhibitor ,Ibrutinib ,